Fig. 3From: Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysisExpected net monetary benefit (€) of the different one-way scenarios for the intervention in the base scenario with 20-year timeframe using a cost-effectiveness threshold of 50,000 €/QALYBack to article page